Suppr超能文献

用于联合疫苗中无细胞百日咳抗原体外特性分析的多重免疫测定法。

Multiplex immunoassay for in vitro characterization of acellular pertussis antigens in combination vaccines.

作者信息

Agnolon Valentina, Bruno Cristina, Galletti Bruno, Mori Elena, Ugozzoli Mildred, Pergola Carlo, O'Hagan Derek T, Baudner Barbara C

机构信息

Novartis Vaccines and Diagonstics SrL (a GSK Company), Via Fiorentina 1, 53100 Siena, Italy; Università degli Studi di Padova, 35129 Padova, Italy.

Novartis Vaccines and Diagonstics SrL (a GSK Company), Via Fiorentina 1, 53100 Siena, Italy; Università di Siena, 53100 Siena, Italy.

出版信息

Vaccine. 2016 Feb 17;34(8):1040-6. doi: 10.1016/j.vaccine.2016.01.012. Epub 2016 Jan 17.

Abstract

Vaccines characterization is required to ensure physical, chemical, and biological integrity of antigens and adjuvants. Current analytical methods mostly require complete antigen desorption from aluminum-based adjuvants and are not always suitable to distinguish individual antigens in multivalent formulations. Here, Luminex technology is proposed to improve the analytics of vaccine characterization. As proof of concept, TdaP (tetanus, diphtheria and acellular pertussis) combination, adjuvanted with aluminum hydroxide, was chosen as model formulation to quantify and determine the level of adsorption of acellular pertussis (aP) antigens onto adjuvant surface at the same time. The assay used specific antibodies bound to magnetic microspheres presenting unique digital signatures for each pertussis antigen, allowing the simultaneous recognition of respective antigens in the whole vaccine, avoiding laborious procedures for adjuvant separation. Accurate and reproducible quantification of aP antigens in TdaP vaccine has been achieved in the range 0.78-50 ng/mL, providing simultaneously information on antigen identity, quantity, and degree of adsorption to aluminum hydroxide. The current study could further be considered as a model to set up in vitro potency assays thus supporting the replacement of animal tests accordingly to the 3Rs concept.

摘要

疫苗特性鉴定对于确保抗原和佐剂的物理、化学及生物学完整性是必要的。当前的分析方法大多要求抗原从铝基佐剂中完全解吸,并且并不总是适用于区分多价制剂中的单个抗原。在此,提出采用Luminex技术来改进疫苗特性分析。作为概念验证,选择用氢氧化铝佐剂的Tdap(破伤风、白喉和无细胞百日咳)联合疫苗作为模型制剂,以同时定量并确定无细胞百日咳(aP)抗原在佐剂表面的吸附水平。该检测使用与磁珠结合的特异性抗体,每个百日咳抗原都有独特的数字信号,能够同时识别整个疫苗中的各个抗原,避免了繁琐的佐剂分离程序。在0.78 - 50 ng/mL范围内实现了Tdap疫苗中aP抗原的准确且可重复的定量,同时提供了关于抗原身份、数量以及对氢氧化铝吸附程度的信息。当前的研究可进一步被视为建立体外效力检测的模型,从而根据3R原则支持替代动物试验。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验